Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Wu, Jun, Lou, Yuqing, Shi, Qin, Xu, Jun, Zhang, Lele, Nie, Wei, Qian, Jie, Wang, Yanan, Zhang, Yanwei, Jiao, Jing, Zhang, Xueyan, Zhang, Wei, Wang, Huimin, Chu, Tianqing, Zhong, Hua, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/
https://www.ncbi.nlm.nih.gov/pubmed/35906676
http://dx.doi.org/10.1186/s40364-022-00400-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/
https://www.ncbi.nlm.nih.gov/pubmed/35906676
http://dx.doi.org/10.1186/s40364-022-00400-5

Ejemplares similares